Overview
AMRX market data
Price History
AMRX price chart
Valuation & Profitability
- P/E (TTM)
- 45.16 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.22 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 4.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.96 – $19.26 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $5.5B · P/B 140.74 · P/S 1.81.
Company News
8-K filing — Amneal Pharmaceuticals, Inc. (AMRX)SEC EDGAR · Aug 3, 2026, 8:28 PM
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25Benzinga · Aug 3, 2026, 7:46 PM
Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050B-$3.150B to $3.100B-$3.200B vs $3.103B EstBenzinga · Jul 30, 2026, 10:00 AM
Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M EstimateBenzinga · Jul 30, 2026, 10:00 AM
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?Benzinga · Jul 24, 2026, 10:25 AM
Shares of generic drug companies are trading lower after President Trump announced that imported generics will be subject to a 100% import tariff following a two-year grace period in order to encourage reshoring of pharma manufacturing.Benzinga · Jul 22, 2026, 4:27 PM
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and PresentationsGlobenewswire Inc · Jul 17, 2026, 12:15 PM
Amneal Pharma Secures FDA Approval For Additional Strengths And Vial Presentations Of Iohexol Injection; Co. Plans To Launch These Products In Q3 Of 2026Benzinga · Jul 17, 2026, 12:02 PM
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23Benzinga · Jul 15, 2026, 3:47 PM
Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without PenaltiesBenzinga · Jul 8, 2026, 12:15 PM